F ollicular lymphoma is the second most frequent form of non-Hodgkin lymphoma and, in spite of its indolent nature, remains mostly incurable 1 . This lymphoma derives from B lymphocytes that have participated in germinal centres (GCs), transient anatomical structures formed primarily by B and T cells during the humoral response to infection and immunization 2 . The GC enables the production of high-affinity antibodies by iterative rounds of a two-step process consisting of affinity-based selection of antibody-producing B cells, which requires paracrine signals from follicular helper T (Tfh) cells, followed by proliferation and programmed mutation of the immunoglobulin locus in selected B cells 3-6 . Importantly, FL maintains a follicular architecture reminiscent of the GC, and non-B lymphocyte cellular components of the GC, including Tfh, are also present in the FL 7 . Ninety percent of FLs harbour a t(14;18) chromosome translocation that leads to the overexpression of the anti-apoptotic gene BCL2 by placing it under the control of the immunoglobulin heavy chain enhancer 8 . Additional genetic alterations include mutations in the epigenetic regulators KMT2D, ), and genes involved in the interaction with the microenvironment of both FL and aggressive lymphoma, such as TNFRSF14, B2M and CD58 (refs. 9, [14] [15] [16] [17] [18] ).
and cytokines further activated mTORC1 activity in all cells, indicating that, as in MEFs, the presence of amino acids was only partially dispensable for mTORC1 activation in the mutant B cells. For a comparison, we performed these signalling experiments side-byside with B cells expressing the tool RagA GTP (Q66L) mutation in heterozygosity and homozygosity. We have previously shown 31 that mTORC1 in MEFs and neonatal tissues from RagA GTP/GTP mice was completely insensitive to nutrient starvation; this was also evident in RagA GTP/GTP B lymphocytes (Fig. 1d ). Heterozygous RagA GTP/+ cells, in contrast to RagC S74C/+ and RagC T89N/+ cells, showed no detectable signalling perturbation ( Fig. 1d and ref. 31 ). The partial resistance to amino acid, leucine and arginine withdrawal was also observed in whole-protein extracts from stimulated B cells (Fig. 1e ). Collectively, these results show that RagC mutations, when expressed endogenously and in heterozygosity, have a modest but significant activating effect on the regulation of mTORC1 by nutrients, while the presence of an activating mutation in RagA in heterozygosity is inconsequential. These data, generated without relying on the limitations of heterologous expression systems, provide cellular evidence for a biochemical asymmetry of the Rag heterodimeric components toward the control of mTORC1 activation, and are consistent with previous in vitro studies 26 . In addition, they provide a potential explanation for the exclusive occurrence of RRAGC heterozygous mutations, and the absence of mutations in RRAGA in human FL.
Because the expression of the point-mutant RagC variants is not restricted to B lymphocytes, we next quantified the proportions of different populations of the haematopoietic lineage, to exclude potential consequences of the expression of these variants in non-B cell populations. Lymphoid (B cells, CD4 + and CD8 + T cells) and myeloid (granulocytes, macrophages, myeloid cells and myeloidderived suppressor cells) populations were present in RagC mutant mice in frequencies similar to those of wild-type counterparts, in both spleen and bone marrow (BM) ( Supplementary Fig. 1h ). Hence, while these quantifications are not a thorough functional examination of all populations in the haematopoietic lineage, it is apparent that the endogenous expression of RagC mutations has no obvious effect on lymphoid and myeloid lineages that could complicate further functional studies on B cells.
RagC mutations accelerate FLs that are sensitive to rapamycin. We next bred RagC mutant S74C and T89N strains with the transgenic mouse strain VavP-Bcl2, which expresses Bcl2 under the lymphoid lineage-specific promoter VavP (VavP-Bcl2 tg ), the standard genetic tool to generate autochthonous FL in mice 34 . The partial insensitivity to amino acid withdrawal observed in RagC mutant B cells was also observed in the VavP-Bcl2 background ( Supplementary Fig. 2a ). Latencies to lymphoma development of VavP-Bcl2 tg ; RagC S74C/+ and VavP-Bcl2 tg ; RagC T89N/+ mice were significantly accelerated ( Fig. 2a ), which was also true for BM chimeras ( Supplementary Fig. 2b ). Murine FLs were diagnosed by pathognomonic histological features of FL, such as expression of Bcl6 in spleen and lymph nodes, indicating that these tumours were of GC B cell origin (Fig. 2b ). Histological analysis of lymphoid organs from FL-bearing mice of all three genotypes revealed similar incidence ( Fig. 2c ) and spread ( Supplementary Fig. 2c,d) . Lymphoma incidence and spread were also similar in all three genotypes when complete cohorts of mice were euthanized at 250 days ( Fig. 2d and Supplementary Fig. 2e ).
Of note, VavP-Bcl2 mice were also prone to develop autoimmunity 34 , so their limited overall survival was due to occurrence of FL and/or autoimmune disease. To our surprise, in addition to the acceleration of FL development, we observed that VavP-Bcl2 tg ; RagC S74C/+ and VavP-Bcl2 tg ; RagC T89N/+ mice and BM chimeras also exhibited shortened latency to autoimmunity ( Supplementary Fig. 2f ). Consistent with the acceleration of both prevalent pathologies in VavP-Bcl2 mice, overall survival (including lymphoma-free and , arginine or leucine in RPMI supplemented with dialysed FBS for 30 min and re-stimulated for 10 min. Whole-cell protein lysates were immunoblotted for the indicated proteins. Quantification of P-S6K1 relative to the levels in RagC +/+ cells without amino acids is shown. b, Same as a, but MEFs were deprived of all amino acids for the indicated times. Quantification of P-S6K1 is shown for n = 3 independent MEFs per genotype. A statistically significant increase in mTORC1 signalling was found for 10 autoimmunity-free) was significantly shorter in VavP-Bcl2 tg ; RagC mut (RagC S74C/+ and RagC T89N/+ ) mice ( Fig. 2a and Supplementary  Fig. 2g ). These results suggest that deregulation of the nutrient sensing pathway deeply affects B cell functions to promote not only FL but also other pathological outcomes of aberrant B cell activation, such as autoimmune disease. Considering that the expression of the mutations is neither conditional nor restricted to B cells, the striking similarities of latencies and diagnoses of RagC mut mice and RagC mut BM chimeras support a negligible impact of systemic expression of the mutations in B cell biology and lymphomagenesis.
To investigate the mechanisms underlying the oncogenicity of RagC mut , we sorted B220 + cells from VavP-Bcl2 tg ; RagC mut and RagC wt FLs and performed transcriptional profiling analysis. The agnostic gene-set enrichment analysis (GSEA) 35 showed the expected mTORC1 signalling signature enrichment in RagC mutant FL cells, together with other signatures consistent with mTORC1 activation, such as translation, c-myc targets and suppression of lysosomal biogenesis ( Fig. 2e , see details of the signatures in Supplementary Table 1 ). We next performed a side-by-side comparison of transcriptional profiles obtained from murine and human FL samples of RagC wt and RagC mut genotypes 20 and observed that mRNAs selectively upregulated in murine RagC mutant FL samples were consistently enriched in RRAGC mutant human FL (and vice versa for downregulated genes (Fig. 2f ), supporting the translational relevance of analysing RagC mutant mice for understanding human FL.
We reasoned that the mTOR inhibitor rapamycin would be particularly efficacious against FL arising in RagC mutant mice, and we administered rapamycin orally starting at 220 days to a cohort of VavP-Bcl2 tg ; RagC mut and VavP-Bcl2 tg ; RagC wt mice and monitored their survival thereafter. Rapamycin treatment strongly suppressed the phosphorylation of S240/244 of S6, a readout of mTORC1 signalling, in all lymphomas ( Supplementary Fig. 2h ). Importantly, the incidence and grade of lymphomas were lower in the rapamycin-treated RagC mut mice, compared with untreated controls (Fig. 2g) , with no statistical change in the incidence or the grade of lymphomas arising in RagC wt mice. Pharmacological inhibition of mTORC1 did not extend the survival of mice with lymphomas of all grades ( Supplementary Fig. 2i ), but, interestingly, when we limited the analysis of lymphoma-free survival to mice with lymphomas of higher grade (grade II/III FL and FL/diffuse large B cell lymphoma (DLBCL), Fig. 2g ), rapamycin selectively extended the survival of VavP-Bcl2 tg ; RagC mut mice, but not that of VavP-Bcl2 tg ; RagC wt mice ( Fig. 2h ). A short oral rapamycin treatment (for 7 days starting at 220 days) induced acute shrinking of spleens and a strong cell-cycle arrest, as measured by Ki67 staining, both in VavP-Bcl2 tg ; RagC wt and VavP-Bcl2 tg ; RagC mut mice ( Supplementary  Fig. 2j ,k). Importantly, and supporting a selective antitumoral effect of rapamycin for RagC mut mice, only the spleens of treated RagC mut mice were significantly smaller after long-term rapamycin treatment ( Supplementary Fig. 2j ). Finally, and without a detectable pro-apoptotic effect ( Fig. 2i ), long-term rapamycin treatment inhibited proliferation selectively in RagC mut FL (Fig. 2j ), a selectivity also seen in the quantification of tumour burden ( Supplementary  Fig. 2l ). Altogether, these data strongly support a selective longterm sensitivity to mTORC1 inhibition in tumours with activating mutations in the nutrient signalling pathway, and this sensitivity may be more profound in FL of higher grade.
As a whole, the results in Fig. 2 provide bona fide support for a critical oncogenic role for the RRAGC mutations in human FL. Moreover, our results show features of selective sensitivity of Rragc mutant FL to pharmacological inhibition of mTORC1 in vivo. Hence, our data nominate mutations in the nutrient signalling pathway as potential markers for patients who would benefit from treatment with mTOR inhibitors.
B cell functions are exacerbated in RagC mutant mice. To determine whether RagC mutations would drive aberrant B cell function in the context of physiological humoral responses, we analysed the primary response of RagC mutant B cells to intraperitoneal immunization with sheep red blood cells (SRBC) to induce GC formation ( Supplementary Fig. 3a ). We observed an approximately threefold increase in abundance of GC B cells in the spleens of RagC S74C/+ and RagC T89N/+ mice compared with RagC +/+ mice at 10 days after immunization, close to the peak of the GC reaction ( Fig. 3a ). Histological analysis and immunohistochemical staining of spleen sections for the GC marker Bcl6 showed that GCs were both larger and more abundant in RagC mutant mice ( Fig. 3a and Supplementary  Fig. 3b ). In contrast, activating mutations in RagA, which is not mutated in human FL, either in heterozygosity or in homozygosity, led to no measurable GC enlargement under similar conditions ( Supplementary Fig. 3c ), indicating an exquisite sensitivity of B cells to different degrees of activation of the nutrient signalling pathway. GC formation leads eventually to differentiation of GC B cells into antibody-secreting plasma cells (PCs). Accordingly, RagC mutant mice showed an approximately threefold increase in the abundance of splenic PCs (Fig. 3b ). Consistent with increased PC production in RagC S74C/+ and RagC T89N/+ mice, the titre of class-switched, IgG1 antibodies in serum quantified 10 days after immunization was markedly increased compared with that of RagC +/+ mice (Fig. 3c ). The exacerbated humoral response to SRBC in RagC mutant mice was sensitive to rapamycin treatment, when administered for the entire humoral response period assessed (10 days) and when restricted to the last 2 days, after GC entry ( Supplementary Fig. 3d ). Collectively, these results show that RagC mutations enhance the humoral response to SRBC, but do not block differentiation of GC B cells to PCs. Constitutive activation of the mTORC1 pathway by expression of RagA GTP or by deletion of Tsc1 in B cells is detrimental to affinity maturation 36 and outcome of the GC reaction, together with the production of memory B cells. This impairment occurs presumably because constitutive mTORC1 activity in all GC B cells, instead of its selective dynamic increase in cells with comparatively higher affinity antibodies, precludes affinity-based positive selection 36 .
To determine whether affinity maturation was also impaired in mice with mutations in RagC, we immunized mice intraperitoneally with the hapten-carrier complex 4-hydroxy-3-nitrophenylacetyl-keyhole limpet haemocyanin (NP-KLH) in alum, and quantified the increase in high-affinity NP antibodies in serum over a 28-day period by affinity-dependent enzyme-linked immunosorbent assay (ELISA) ( Supplementary Fig. 3e) . Surprisingly, and in contrast to decreased high-affinity titre of antibodies of RagA GTP and Tsc1 knockout models of deregulated mTORC1 activity 36 , RagC S74C/+ and RagC T89N/+ mice showed increased production of high-affinity antibodies to NP (Fig. 3d ). Next, we determined whether exacerbated B cell functions were also at work in mice expressing RagC mutations in the context of overexpression of BCL2, but before the onset of FL. We first quantified spontaneous GC formation in unimmunized mice, readily observed in VavP-Bcl2 tg ; RagC wt controls 34 , and observed a significant expansion of GC area in VavP-Bcl2 tg ; RagC mut (Fig. 3e ). Moreover, 10 days after SRBC immunization we observed a similar approximately two-to threefold expansion in GC B cells in VavP-Bcl2 tg ; RagC mut (Fig. 3f ). These results indicate that exacerbated B cell activation caused by endogenous expression of RagC mutations also occurs in the cellular context of Bcl2 overexpression, which will result in follicular lymphomagenesis.
CD43-Resting B cells
Altogether, the results obtained with SRBC and NP-KLH immunizations show that RagC mutant mice have an exacerbated humoral response, with increased GC size and cellularity and PC production, but without impaired selection of high-affinity B cells or compromised production of high-affinity antibodies. Hence, a mild, partial gain-of-function in the nutrient signalling arm of mTORC1 favours expansion of activated B cells, even in the context of Bcl2 overexpression. This aberrant behaviour is consistent with the oncogenic potential of RagC mutations, and contrasts to the cell-intrinsic deleterious effects of more profound perturbations in mTORC1 activity as elicited by RagA GTP or loss of Tsc1 (ref. 36 ).
Enhanced B cell activation in RagC mutants is cell intrinsic.
To ascertain whether RagC mutant cells had a competitive advantage relative to RagC wild-type cells, as suggested by the results of immunization ( Fig. 3 ), we performed competitive reconstitution in lethally irradiated hosts by co-injecting RagC +/+ and either RagC S74C/+ or RagC T89N/+ BM cells in a 1:1 ratio, traceable by the differential expression of CD45.1 and CD45.2 (Fig. 4a ). The behaviour and abundance of RagC mutant cells during competitive haematopoiesis, B cell lineage development and immunization and GC formation were then monitored. We first determined the contribution to lymphoid populations (mature B and T lymphocytes) in the spleen 2 months after reconstitution by cell surface immunostaining of the alleles CD45.1 and CD45.2. We observed that cells of the RagC mutant genotype marginally but significantly outnumbered wild-type cells in the B220 + naïve B cell compartment ( Supplementary Fig. 4a ), while showing no competitive advantage in generating T cells ( Supplementary  Fig. 4a ). More importantly, when we immunized the mixed chimeras with SRBC, we observed a greater enrichment of RagC mutant cells in the GC B cell population (~18-fold for RagC S74C/+ ; and ~27-fold for RagC T89N/+ ). A similar enrichment was found in the PC population (~14-fold for RagC S74C/+ ; ~14-fold for RagC T89N/+ ) (Fig. 4b,c and Supplementary Fig. 4b,c ). Monitoring of mTORC1 activity in different B cell populations (naïve, GC and PC) showed increased phospho-S6 in RagC mut cells compared with RagC wt cells cohabiting the same spleen (Fig. 4d) . In contrast to the competitive advantage of B cells, RagC mutant GC-resident T lymphocytes (follicular helper T cells, Tfh) were only marginally, and not significantly, enriched over wild-type competitors ( Supplementary  Fig. 4d ), with no significant differences in mTORC1 activity ( Fig. 4d ). Together, our results show that RagC mutations confer a modest but significant increase in mTORC1 activity in B cell populations, which is associated with increased competitiveness of mutant B cells during B cell lineage development, and, markedly, during the GC response. The increased fitness of RagC mutant GC B cells is prone to playing a role in enriching the population of RagC mutant cells during the multiple cellular competition events occurring during the protracted course of the development of FL.
In contrast to the strong effects on B cells, RagC mutations had minimal impact on T cell development or Tfh differentiation, suggesting that B cell phenotypes are strongly cell autonomous. In addition, these results suggested that RagC mutant B cells may be less dependent on T cell help for activation. To test this, we mimicked T cell help to B cells in vitro by incubation with anti-CD40 ( Fig. 4e ). This treatment elicited several features of enhanced dosedependent activation of RagC mutant B cells, such as increased proliferation, measured by EdU incorporation and by carboxyfluorescein succinimidyl ester (CFSE) label decay, increased classswitch recombination to IgG1 and increased PC differentiation, as measured by expression of PC surface marker CD138 and intracellular Prdm1 (Fig. 4f-j and Supplementary Fig. 4e -i). As seen in vivo ( Supplementary Fig. 3d ) and as expected, in vitro activation of mice by using CD43 magnetic beads. CD43 − cells were stimulated with anti-CD40 and IL-4. Three days after activation, the following parameters (f-j) were quantified. f, S phase determined by EdU incorporation in CD19 + cells (n = 3 for RagC +/+ and RagC S74C/+ ; n = 5 for RagC +/+ and n = 4 for RagC T89N/+ ). g, Proliferation by CFSE staining in B220 + cells (n = 3 for RagC +/+ and RagC S74C/+ ; n = 5 for RagC +/+ and RagC T89N/+ ). h, Quantification of class-switched B220 + IgG1 + cells (n = 6 for RagC +/+ and RagC S74C/+ ; n = 3 for RagC +/+ and RagC T89N/+ ). CSR, class-switch recombination. i, PC production by expression of cell surface marker CD138 in B220 low cells (n = 6 for RagC +/+ and RagC S74C/+ ; n = 6 for RagC +/+ and n = 5 for RagC T89N/+ ). j, PC production by intracellular immunostaining of PRDM1 in B220 low CD138 + cells quantified by flow cytometry. n = 3 mice per genotype. MFI: median fluorescence intensity. k, Experimental set-up for determining cell-intrinsic effects of RagC mutations using mixed BM chimeras with the Ighm μMT genetic system 37 . BM reconstitution of lethally irradiated CD45.1.1 hosts, by co-injecting Ighm μMT/μMT (CD45.1.2) and either RagC +/+ , RagC S74C/+ or RagC T89N/+ (CD45.2.2) BM cells in a 9:1 ratio. After 8 weeks, mice were immunized with SRBC. Quantification of GC B cells (B220 + CD95 + GL7 + ) (l) and PC (B220 low CD138 + ) (m), in spleens collected from Ighm μMT/μMT : RagC +/+ , RagC S74C/+ or RagC T89N/+ 10 d after immunization (n = 3 mice per genotype). In all panels, lines indicate the mean and statistical significance was calculated by two-tailed Student's t-test.
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B cells and PC differentiation were sensitive to acute rapamycin treatment ( Supplementary Fig. 4j ).
To confirm the B cell-intrinsic causality of exacerbated B cell activation by RagC mutations in vivo, we undertook a genetic approach consisting of BM reconstitution with a majority (85-90%) of Ighm μMT/μMT haematopoietic stem cells (HSCs), which are unable to produce a B cell lineage 37 , mixed with 10-15% of RagC +/+ , RagC S74C/+ or RagC T89N/+ HSC (Fig. 4k ). In this setting, T lymphocytes and all myeloid cells derive almost exclusively from (RagC wild-type) Ighm μMT/μMT HSCs, but the B cell lineage descends entirely from RagC mutant (or wild-type in control mice) progenitors ( Supplementary  Fig. 4k ). When these mixed BM chimeras were immunized with SRBC as before, we observed that expression of RagC S74C or RagC T89N mutations restricted to B cells sufficed to drive the same enhancement in GC formation and size ( Fig. 4l ) and PC generation (Fig. 4m) as observed in single-population RagC mutant BM chimeras and in fullbody RagC mutant mice. Hence, exacerbated B cell activation occurs by the expression of RagC mutants in a cell-intrinsic manner.
RagC mutants show decreased supportive T cell signals. To gain insight into the cellular events underlying the exacerbated B cell activation, we next compared the transcriptional profiles of sorted GC B cells from RagC wild-type and RagC mutant mice. The transcriptome of sorted GC cells arising from RagC mutant and wildtype mice showed a striking overlap with signatures identified in FL cells ( Supplementary Fig. 5a ). This overlap supports the idea that the analysis of the GC reaction is a meaningful mirror of cellular states and processes occurring in FL. Target gene signatures of c-myc, indicative of a state of enhanced B cell activation 38, 39 and synergistic with mTORC1 activity in GC cells 36 , were also observed in RagC mutant GC and FL samples (Figs. 5a, 2e and Supplementary Fig. 5b ). Furthermore, GSEA analysis also showed upregulation of gene signatures related to the activation of mTORC1 in RagC mutant GC, including ribosome biogenesis genes, and genes downregulated in lysosomal biogenesis ( Fig. 5a and Supplementary Fig. 5b ) and downregulated in a human B cell lymphoma line (BJAB) treated with rapamycin or deprived of leucine 41 (Supplementary Fig. 5c ).
GSEA also revealed a signature of suppressed apoptosis in the RagC mutant GCs ( Fig. 5a and Supplementary Fig. 5b ), a process not generally perceived as regulated by mTORC1 (refs. [42] [43] [44] [45] ). However, apoptosis has particular relevance in GC B cells, as programmed cell death is a frequent fail-safe response triggered on poor affinity or lack of T cell help, unresolved DNA damage or self-reactivity 2 . Indeed, the increased GC size and exacerbated B cell response were consistent with increased proliferation, suppressed apoptosis or both. Steady-state proliferation measured within the increased GC B cell population from RagC mutant mice was similar to that of wild-type mice ( Supplementary Fig. 5d ), suggesting that decreased death, rather than increased division, could partially explain the increase in the GC B cell population, and provide an explanation for the oncogenicity of RagC mutations. We validated the suppression of programmed cell death signature in RagC mutant GC B cells by immunostaining against cleaved caspase 3 (C-c3) 10 days after induction of GC by SRBC injection (Fig. 5b and Supplementary  Fig. 5e ). In an attempt to mechanistically connect decreased apoptosis in RagC mutant B cells to an indifference to T cell support, we induced a 'death-by-neglect' fate by injecting a blocking antibody to CD40 ligand (anti-CD40L), the key driver of Tfh help to GC B cells 36, 46, 47 . During the B-to-T synapse, ligation of the CD40 receptor in B cells activates several signalling cascades, including PI3K-Akt. Injection of anti-CD40L into mice previously immunized with SRBC ( Fig. 5c ) resulted in increased apoptosis, but significantly less so in RagC mutant versus wild-type chimeras, as determined by quantification of Bcl6/C-c3 double-positive GC B cells (Fig. 5b) . Importantly, this reduction in apoptosis was not a reflection of a general resistance to cell death, as γ-irradiation with 5 Gy induced equally large amounts of Bcl6/C-c3 positive cells in wild-type and RagC mutant GC B cells ( Supplementary  Fig. 5f ). This result indicates that RagC mutant GC B cells are intrinsically resistant to apoptosis on withdrawal of T cell help, and is consistent with a reduced need for microenvironmental activating Tfh signals in RagC mutant B cells. Indeed, while the overall abundance of Tfh gated on its parental CD4 + population is not decreased in RagC mutant mice, the relative abundance of supportive Tfh cells in GC is markedly decreased because of the massive expansion of the GC, as evidenced by a higher ratio of GC B cells to Tfh cells determined by flow cytometry (Fig. 5d ), and by lower Tfh abundance per GC area by immunostaining with the Tfh marker PD1 (Fig. 5e ), again supporting that a relative reduction in follicular T help is well tolerated in RagC mutant B cells. We did not find evidence for transcriptional changes in RagC mut GC cells in genes known to be involved in B-to-Tfh cross-talk in the GC synapse (Supplementary Table 2 ), supporting that B cells are less dependent on Tfh signals without paracrinally repelling Tfh or affecting their function [48] [49] [50] [51] .
Increased independence of GC B cells from Tfh cell signals conferred by RagC mutations may or may not be meaningful in the context of FL induced by VavP-Bcl2 tg , particularly if this independence is related to a suppression of apoptosis. To test this possibility, we first quantified steady-state apoptosis in GC induced on immunization in VavP-Bcl2 tg ; RagC wt or mut mice. While apoptosis was suppressed by the expression of VavP-Bcl2, regardless of the RagC mutational status, we observed that VavP-Bcl2 tg ; RagC mut mice had significantly lower C-c3 compared with their VavP-Bcl2 tg ; RagC wt counterparts ( Supplementary Fig. 5g ). Next, we quantified Tfh cells in murine FL samples. RagC mutant FL showed a similar decrease in the abundance of Tfh cells by IHC ( Fig. 5f ) and by flow cytometry (CXCR5 + PD1 + Foxp3 − ) ( Supplementary Fig. 5h ), again, without transcriptional changes in B-to-T signals (Supplementary Table 2 ).
We then analysed collections of untreated human FL biopsies harbouring mutations in RRAGC, and observed a similar decrease in the abundance of PD1-positive T cells in the follicular areas of these tumours (RagC wt : 28 cases, RagC mut : 16 cases; Fig. 5g and Supplementary Fig. 5i ). The decrease in Tfh cell abundance was even stronger when samples harbouring co-occurring mutations in RRAGC and the lysosomal v-ATPase, both involved in the control of mTORC1 activation 52 , were grouped ( Supplementary Fig. 5j ).
Finally, loss of TNFRSF14 (HVEM) function (by genetic loss or mutation) is a frequent lesion in human FL because it induces a tumour-supportive microenvironment that includes increased Tfh cellularity 14 . If our hypothesis of RagC mutations conferring some degree of independence toward T cell help is true, then loss of TNFRSF14 would be functionally redundant with mutations in RRAGC, and hence these two genetic events would be unlikely to be co-selected in the same patient sample. Hence, we performed a meta-analysis of all four reports of human FL samples for which information regarding the genomic mutational landscape, including the status of RRAGC and TNFRSF14, was available 17, 19, 20, 40 and found that these two genetic lesions were mutually exclusive ( Fig. 5h ; P = 0.0012). Because TNFRSF14 can be inactivated by mutation or deletion, we performed an additional validation with a cohort of FL samples for which we obtained deletion plus mutation information for TNFRSF14, plus mutational data on RRAGC. In this cohort of 109 cases we validated the existence of mutual exclusivity between RRAGC mutations and TNFRSF14 mutations or deletions (Fisher's exact test: P = 0.0367; Supplementary Fig. 5k ). Together, the lower abundance of Tfh cells from the tumour microenvironment and the mutually exclusive genetic alterations in RRAGC and HVEM suggest that FL may rely on alternative avenues to support its growth, by attracting Tfh cells by loss of HVEM or autonomously activating intracellular pathways that synergize with, and thus decrease its need for, Tfh cell-derived signals by mutations in RRAGC (Fig. 6 ).
Discussion
Using genetically engineered mice, we provide bona fide evidence for an oncogenic role of the Rag GTPase pathway. The exclusiveness of recurrent mutations in RRAGC in human B cell lymphomas (FL, and a smaller percentage of DLBCL) suggests that B lymphocytes are exquisitely sensitive to perturbations in the nutrient sensing pathway. Our previous work in mice with genetic deletion 53 and constitutive activation 36 of RagA showed striking phenotypic aberrations in the B cell lineage and severe impairment of B cell competitiveness in the GC and, consequently, of the entire antibody response. This was paradoxical, given that strong physiological activation of mTORC1 was a requirement for positive selection of GC B cells. Our present data clarify this apparent paradox, by showing that more modest activation of the mTORC1 pathway afforded by patient-derived mutations in RagC provides the correct 'dose' of mTORC1 hyperactivation required to increase rather than decrease GC B cell fitness, and suggests an explanation for why gain-of-function mutations in RagA do not arise in primary lymphomas 31 . Thus, the use of genetically engineered mice expressing RagC mutations under endogenous control and physiological levels revealed an exquisite sensitivity of B cells to different degrees of activation in the nutrient signalling pathway. The sudden burst of growth and proliferation that occurs on B cell activation during the GC reaction, driven by c-myc, PI3K-Akt and NF-κB 36, 38, 39, 46, 54, 55 , among other pathways, depends on an adequate nutrient and energetic supply to sustain the associated anabolic needs. Hence, proper sensing of nutrient sufficiency is imperative to match the extent of the burst to nutrient availability and anabolic capacity, while mismatches caused by excessive activation of the mTORC1 pathway would lead to loss of competitiveness. In this regard, a complete inability to integrate nutrient-level cues in the control of mTORC1 could result in an energetic catastrophe during anabolism and proliferation, whereas a mild increase in nutrient signalling may offer a competitive advantage, if still retaining the ability to respond to dramatic fluctuations in nutrient levels, as oncogenic mutations in RRAGC do.
It was recently shown that GC B cells are intrinsically resistant to activation of mTORC1 in response to T cell help via the PI3K-Akt axis, at least when compared with naïve B cells 46 . The two independent arms upstream of mTORC1-PI3K-Akt downstream of BCR and Tfh cell help and activating mutations in the nutrient sensing pathway-significantly synergize, but do not substitute each other (Fig. 6 ). As predicted, given the decreased requirement for T cellmediated signals for B cell activation, RagC mutations correlated with decreased presence of Tfh cells (PD1 + T lymphocytes) in both RagC mutant FL samples and human RRAGC mutant FL samples ( Fig. 5 ).
We found little evidence of direct control of mTORC1 over proliferation of GC B cells in vivo, consistent with previous results from us and others 36, 56, 57 , albeit more proliferating GC cells were present in RagC mutant mice at all times due to the extraordinary enlargement of the GC B cell population. Transcriptional profiling and functional experiments in GC B cells support a role for RagC mutations in the suppression of apoptosis, even when the antiapoptotic protein BCL2 was overexpressed (Fig. 5 ). We postulate that increased mTORC1 activity reinforces B cell activation by T cell help, and suppression of apoptosis is one of the outcomes of B cell activation, probably a critical one in the long process of follicular lymphomagenesis, but not the only one. Indeed, when FL-bearing mice were treated with rapamycin, we observed a selective extension of survival that occurred with a decrease in proliferation of RagC mutant FL cells (Fig. 2) , and without a significant increase in C-c3 positive cells. This could be indicative of increased resistance to programmed cell death in established lymphomas when compared with GC B cells, including those GC B cells that overexpress Bcl2. It is also consistent with an early induction of apoptosis with rapid turnover on pharmacological inhibition of mTORC1, followed by a halt in proliferation among remaining viable cells, in line with the well-established cytostatic effects of mTORC1 inhibitors.
Loss-of-function mutation or deletion of TNFRSF14 in FL induces a supportive microenvironment that includes abundant Tfh 14 , which would be partially redundant with RRAGC mutations if they confer some degree of independence from Tfh signals. Indeed, mutual exclusiveness of RRAGC and TNFRSF14 mutations was precisely what we observed when we performed a meta-analysis of available mutational data on RRAGC and TNFRSF14 (Fig. 5 ). It will be worthwhile to evaluate the interplay between the supportive FL microenvironment, as an inheritance of the requirements of GC B cells, and the autochthonous immune response against FL.
Altogether, we demonstrate that a mild increase in nutrient signalling upstream of mTORC1 has dramatic consequences for FL development and sensitizes toward mTORC1 inhibitors. Our work suggests that pharmacological inhibition of mTORC1 with rapalogs or ATP-competitive inhibitors may be particularly efficacious for the 15% of FL harbouring activating mutations in the nutrient signalling pathway. This percentage may be an underestimation, if other genetic lesions or epigenetic means of activating the nutrient signalling pathway are at work in FL patients without RRAGC mutations. Clinical trials with rapalogs as monotherapy have been performed recently in FL [58] [59] [60] , with a fraction of patients showing impressive responses. These intriguing clinical observations, viewed in the context of our work and the existence of oncogenic mutations in RRAGC, trigger speculative thoughts, such as whether the biologic underpinnings of the mTOR dependencies and drug response in FL may be determined precisely, at least in part, by the mutational status of genes involved in this nutrient sensing. It remains to be determined whether non-genetic perturbations in nutrient signalling (as in the case of chronically increased or decreased nutrient levels) would significantly impact the biology of GC and FL cells. Epidemiology-based connection between elevated nutrient intake, body mass index and B cell lymphoma is far from clear, with reports showing opposite conclusions [61] [62] [63] [64] . The humoral response is affected by body mass index in humans and rodents 65, 66 . Hence, further research is needed to examine if therapeutic manipulation of nutrient levels may serve as a means of modulating the humoral response and, indeed, if this provides a novel strategy against FL tumours.
Methods
Generation of RagC CRISPR-edited KI mice.
To introduce the patient-derived RRAGC mutations, C57BL/6 mouse blastocysts were injected with Cas9 mRNA, a single-guide RNA (sgRNA) targeting the sequence of interest (mouse Rragc) and a single-stranded DNA oligonucleotide (ssDNA) containing the desired mutation flanked by 40-60 bases homologous to the sequence adjoining the DNA doublestrand break. Following clone selection, genotyping was performed by specific PCR followed by restriction fragment length polymorphism or Sanger sequencing.
Sequences used: For RagC-S74C: TCC→AAC s sD NA: C GG CC CG GG CG GC GC TG AC AG CT CC AA GC CG AG GA TC CT GC TT AT GG GG CT CC GG CG CA GC GG CA AA AA CA GT AT CC AA A AA g tg ag cg cc cc gc ag ccgccgcctgcccttggttttgcccggcccacggcgctcaggtggcgggt gRNA: CGGCAAATCCTCCATCCAGA For RagC-T89N: ACT→AAT s sD NA c tt gtatagttaaatagttacaaagttgtctctgtttctcctcacagGTGGTGTTTCATAAGATGTC ACCCAATGAGAATCTGTTCCTAGAAAGTACCAACAAGATTTATAAAGATG ACATTTCCAACAGCTCCTTTGTGAACTTCCA gRNA: ACCCAATGAGACTCTCTTTT Mice. All animal procedures carried out at the CNIO were performed according to protocols approved by the CNIO-ISCIII Ethics Committee for Research and Animal Welfare (CEIyBA). Ighm μMT mice 37 were obtained from Jackson Laboratories (JAX stock no. 002288). Mice were housed under specific pathogenfree conditions at 22 °C and with 12-h dark/light cycles (light cycle from 8:00 to 20:00). Mice were fed with a standard chow diet (Harlan Teklad 2018). All mice were observed weekly by trained personnel. On signs of morbidity, mice were closely inspected daily until application of humane end-point criteria (http:// dels.nas.edu/global/ilar/Guide) in consultation with veterinary staff. From our experience, the humane end point is applied when the life expectancy of the mice is, on average, shorter than one week. No maximal tumour volume criteria were used because health decline caused by FL always precedes the growth of measurable bulky tumours. Rapamycin was supplied encapsulated in chow diet at 42 ppm (Rapamycin Holdings and Purina Lab Diet).
Immunizations and mouse experimentation. For the generation of GC response, 8-10-week-old mice were immunized by intraperitoneal (i.p.) injection of (1 × 10 9 ) SRBC (Oxoid, catalogue no. SR0053B) in PBS or 50 µg of 4-hydroxy-3-nitrophenylacetyl conjugated to keyhole limpet haemocyanin (NP-KLH, BioSearch, catalogue no. N-5060-5) in alum adjuvant (Thermo Scientific, catalogue no. 77161) (2:1) and analysed at day 10.
To generate larger amounts of GC B cells (that is, for gene expression profiling), we did two sequential i.p. SRBC injections (day 0, 5 × 10 8 ; day 5, 1 × 10 9 ) and collected cells at day 12. This protocol yielded about three to four times more GC B cells (~12-15% of the B cell fraction) than with a single immunization.
For the memory response assays, mice were immunized by intraperitoneal injection of 50 μg of NP-KLH in complete alum adjuvant and blood was collected at day 0, 7, 14 and 28.
To measure proliferation in GC B cells, mice were immunized by intraperitoneal injection of (1 × 10 9 ) SRBC, and after 10 d, 2 h before sacrifice, mice were injected intraperitoneally with 0.5 mg of 5-ethynyl-2′-deoxyuridine (EdU). Analysis of incorporation of EdU was performed using the Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Life Technologies, catalogue no. C10634) following the manufacturer's instructions.
For anti-CD40L-induced apoptosis, mice were immunized by intraperitoneal injection of (1 × 10 9 ) SRBC, and after 10 d, mice were injected intravenously with 200 μg of anti-CD40L agonist antibody (BioXCell, clone FGK4.5).
To study the effect of rapamycin in GC formation, 10-12-week-old chimeric mice were immunized by intraperitoneal injection of (1 × 10 9 ) SRBC and simultaneously treated with encapsulated rapamycin chow diet for 10 d (see Mice) or administered i.p. at 2 mg kg −1 at day 8, before assessment of GC formation by flow cytometry at day 10 (see Supplementary Fig. 3d ).
Diagnose of murine lymphomas and autoimmunity.
Lymphoproliferative diseases developing in the VavP-Bcl2 tg ; RagC mut cohort were diagnosed based on morphology according to the following criteria, analagous to the classification of human lymphoma: (1) early stages of FL (FL in situ), defined by the presence of oversized follicles with partial or absent mantle zone and loss of confinement in the context of a yet-preserved tissue architecture; (2) overt FL of various grades, characterized by the effacement of the nodal and/or splenic architecture by a proliferation of follicle centre B cells, with a follicular growth pattern occupying the medullary and/or paracortical areas; (3) DLBCL, defined by the effacement of the lymphoid organ architecture due to the expansion of large cells, with occasional infiltration beyond the capsule into surrounding soft tissues 67 . FL was classified into the following three histological grades: grade I, 0-5 centroblasts in ×40 field; grade II, 6-15 centroblasts in ×40 field; grade III, >15 centroblasts in ×40 field. Lymph nodes, spleen, bone marrow and other tissues with abnormal mononuclear infiltrate were evaluated. Mice showing numerous grossly enlarged and fused germinal centres replete with more than five germinal centres per nodule of white pulp in the spleen were considered lymphoma. Bcl6 stain was used in doubtful cases to highlight the follicular pattern. The genotype of the animal was not disclosed to the pathologist (A. de Martino and E. Caleiras). Autoimmunity was scored by perivascular inflammatory infiltrate, predominantly mononuclear of lymphoid aspect, with or without necrosis of the vessel wall, and was most prevalently seen in salivary glands and kidney. Autoimmune glomerulonephritis was defined by hypercellular glomeruli containing eosinophilic deposits, generally accompanied by Bowman epithelium hyperproliferation (a representative example is shown in Supplementary Fig. 2d ).
Signalling in MEFs.
For amino acid deprivation experiments, subconfluent cell cultures were rinsed twice and incubated in RPMI (US Biological, catalogue no. R8999-04A) and supplemented with 10% dialysed foetal bovine serum (FBS) and all 20 amino acids during 1 h. After that, cells were rinsed three times and placed in RPMI without amino acids, arginine or leucine, and supplemented with 10% dialysed FBS during the indicated time points. Re-stimulation with amino acids was performed over 10 min. mTORC1 activity in naïve B cells. To study mTORC1 activity in naïve B cells, we isolated CD43 − resting B cells from 8-10-week-old non-immunized mice using magnetic beads, (Myltenyi, catalogue no. 130-049-801) following the manufacturer's instructions. The CD43 − resting B cells (1 × 10 6 ) were plated with B cell media: RPMI (US Biological, catalogue no. R8999-04A) + 10% dialysed FBS + 55 μM β-mercaptoethanol (Gibco, catalogue no. 31350-010) + 10 mM HEPES (Lonza, catalogue no. BE17-737E) + 100 μg ml −1 penicillin/streptomycin (Gibco, catalogue no. 15070-063) containing no amino acids, with or without cytokines (1 μg ml −1 anti-CD40 (R&D Systems, catalogue no. MAB440) and 25 ng ml −1 mouse interleukin-4 (R&D Systems, catalogue no. 404-ML)) during 1 h. After this time, stimulation with amino acids was performed for 30 min and cells where collected and processed for flow cytometry.
Class-switch recombination and differentiation in vitro.
To study the process of class-switch recombination and plasma cell differentiation in activated mouse B cells, we isolated CD43 − resting B cells from 8−10-week-old non-immunized mice using magnetic beads (Myltenyi, catalogue no. 130-049-801) following the manufacturer's instructions. Cells were washed and resuspended in B cell medium: RPMI (Sigma, catalogue no. R8758) + 10% FBS (Hyclone, catalogue no. SV30160.03) + 55 μM β-mercaptoethanol + 10 mM HEPES + 100 μg ml −1 penicillin/ streptomycin containing 1 μg ml −1 anti-CD40 and 25 ng ml −1 mouse interleukin-4. The culture medium was replenished every two days to avoid exhaustion. Four days later, cells were collected and processed for flow cytometry analysis.
To study PRDM1 expression in activated B cells, after 4 d of differentiation, cells were collected and processed for flow cytometry using Alexa Fluor-647 antimouse Blimp-1 detection kit (Biolegend, catalogue no. 149902).
To study the effect of rapamycin in plasma cell production, B cells were treated with 1 nM or 10 nM 48 h before collection and flow cytometry analysis (day 4).
B cell proliferation.
To study cell proliferation in activated B cells, CD43 − resting B cells were labelled with 5 mM CFSE (Life Technologies, catalogue no. C34554) following the manufacturer's instructions. This reagent monitors distinct generations of proliferating cells by a fluorescent dye dilution. Data were acquired at days 2-4 on a FACSCanto II (BD Biosciences) flow cytometer with 488-nm excitation and an emission filter in the 530/30 nm. Alternatively, analysis of EdU incorporation in 3-d activated B cells was performed using the Click-iT Plus EdU Alexa Fluor 647 Flow Cytometry Assay Kit (Life Technologies, catalogue no. C10634) following the manufacturer's instructions. To study the effect of rapamycin in B cell proliferation, B cells were treated with 1 nM or 10 nM 24 h before the addition of EdU (day 3).
Staining and flow cytometry analysis. Mononuclear cell pools were isolated from mouse spleens at the indicated times postimmunization. Cells were separated by crushing the spleens through a 70-μm mesh (Corning) in ice-cold PBS with 0.1% BSA and 3 mM EDTA, and red blood cells were lysed using Erythrocyte Lysis Buffer (Qiagen, catalogue no.79217). Cell staining was performed on ice in PBS with 0.1% BSA and 3 mM EDTA. We included a prior step of incubation with Fc-block Reagent (Anti-CD16/CD32, Pharmigen, catalogue no. 553142). GC B cells were identified within the B cell fraction (B220 + ) as GL7 + CD95 + . Alternatively, GC B cells were identified within the CD19 + cell fraction, as CD95 + CD38 − . Plasma cells were identified by gating on CD138 + , B220 low cells. Granulocytes were identified as B220 − /CD4 − /CD8 − /CD11b − /Gr-1 + . Myeloid-derived suppressor cells were identified as B220 − /CD4 − /CD8 − /CD11b + /Gr-1 + . Myeloid cells were identified as B220 − /CD4 − / CD8 − /CD11b + . Macrophages were identified as B220 − /CD4 − /CD8 − /CD11b low / F4/80 + . Follicular helper T cells (Tfh) were identified as B220 − /CD4 + /CXCR5 + / PD1 + . For the detection of phosphorylated S235/236 of S6 with intracellular staining, cell suspensions were fixed and permeabilized using the Cytofix-Cytoperm and Cytoperm-Wash buffers (BD Biosciences, catalogue no. 554714) and subsequently stained for 120 min at room temperature. Complete information on antibodies used in flow cytometry is shown in Supplementary Table 3 .
All flow cytometry analyses were done at the Flow Cytometry Facility (CNIO), using BD LSR-Fortessa or BD CantoB cell analysers, running BD FACSDiva software (BD Biosciences). FlowJo software (v.9.8.1 and v.10; TreeStar) was used for data analyses and plot rendering. See Supplementary Fig. 6 for details of the gating strategies.
Immunoblotting. Cells were rinsed once with ice-cold PBS and lysed in ice-cold lysis buffer (50 mM HEPES (pH 7.4), 40 mM NaCl, 2 mM EDTA, 1.5 mM sodium orthovanadate, 50 mM NaF, 10 mM pyrophosphate, 10 mM glycerophosphate and 1% Triton X-100 and one tablet of EDTA-free complete protease inhibitors (Roche) per 25 ml). Cell lysates were cleared by centrifugation at 13,000 r.p.m. for 10 min. Protein extracts were denatured by the addition of sample buffer, boiled for 5 min, resolved by SDS-PAGE and analysed by immunoblotting. Western blot analyses were performed according to standard procedures. Antibodies from Cell Signaling Technology were used for detection of P-T389-S6K1 (catalogue no. 9234), S6K1 (catalogue no. 2708), P-S235/236-S6 (catalogue no. 2211), S6 (catalogue no. 2217), P-T37/46-4EBP1 (catalogue no. 2855), 4EBP1 (catalogue no. 9644), P-T308 − AKT (catalogue no. 2965), P-S743-AKT (catalogue no. 4060), AKT (catalogue no. 4691). For detection of β-actin we used an antibody from Sigma (catalogue no. A5441).
Gene expression profiling of GC B cells and FL.
GC B cells (B220 + , CD95 + , CD38 − ) were sorted from RagC mut and RagC wt splenocytes after 12 d of SRBC immunization in a BD FACSAria Ilu (Becton Dickinson) and InFlux (Cytopeia-Becton Dickinson) cell sorters. Total RNA from sorted GC B cells was extracted using TRIzol (Invitrogen, catalogue no. 15596026) and PicoPure RNA Isolation kit (Arcturus, catalogue no. 12204-01) following the manufacturer's instructions. For gene expression profiling of murine lymphomas, B220 + were isolated from mouse lymphoma tumours by immunomagnetic enrichment with CD45R (B220) microbeads (Miltenyi Biotech, catalogue no. 130-049-501).
RagC S74C GC B cell samples. Samples of 500 ng of total RNA were used. The average sample RNA integrity number was 9.75 (range 9.0-10) when assayed on an Agilent 2100 Bioanalyzer. The poly(A) + fraction was extracted from 1 µg of total RNA, randomly fragmented and converted to double-stranded complementary DNA and processed through subsequent enzymatic treatments of end-repair, dA-tailing and ligation to adaptors, as in the Illumina TruSeq Stranded mRNA Sample Preparation Revision D kit (part no. 15031047; this kit incorporates dUTP during second-strand cDNA synthesis, which implies that only the cDNA strand generated during firststrand synthesis is eventually sequenced). The adapter-ligated library was completed by PCR with Illumina PE primers. The resulting purified cDNA library was applied to an Illumina flow cell for cluster generation and sequenced on an Illumina instrument (Illumina HiSeq2500) by following the manufacturer's protocols. Image analysis, per cycle base calling and quality score assignment were performed with Illumina Real Time Analysis software. Conversion of Illumina BCL files to bam format was performed with the Illumina2bam tool (Wellcome Trust Sanger Institute New Pipeline Group (NPG); https://github.com/wtsi-npg/illumina2bam).
RagC T89N GC B and RagC S74C FL samples. Samples of 500 ng of total RNA (but 100 ng for YRT-236, and 200-300 ng for YRT-224, -230 and -235) were used. Average sample RNA integrity number was 8.5 (range 7.9-10) when assayed on an Agilent 2100 Bioanalyzer. The poly(A) + fraction was purified and randomly fragmented, converted to double-stranded cDNA and processed through subsequent enzymatic treatments of end-repair, dA-tailing and ligation to adaptors as in the NEBNext Ultra II Directional RNA Library Prep Kit for Illumina (NEB, catalogue no. E7760) (this kit incorporates dUTP during second-strand cDNA synthesis, which implies that only the cDNA strand generated during first-strand synthesis is eventually sequenced).
The adapter-ligated library was completed by PCR with Illumina PE primers. The resulting purified cDNA library was applied to an Illumina flow cell for cluster generation and sequenced on an Illumina instrument (Illumina HiSeq2500) following the manufacturer's protocols. Image analysis, per cycle base calling and quality score assignment were performed with Illumina Real Time Analysis software. Conversion of BCL files to FASTQ format was performed with the bcl2fastq Software (Illumina).
Sequencing reads were analysed with the nextpresso pipeline (http://bioinfo. cnio.es/nextpresso/) as follows: sequencing quality was checked with FastQC v.0.11.0 (http://www.bioinformatics.babraham.ac.uk/projects/fastqc/). Reads were aligned to the mouse genome (NCBI37/mm9) with TopHat v.2.0.10 (ref. 68 ) using Bowtie v.1.0.0 (ref. 69 ) and SAMtools v.0.1.19 (ref. 70 ), allowing 2 mismatches and 20 multihits. Differential expression was tested with DESeq2 (ref. 71 ), using the mouse NCBI37/mm9 transcript annotations from https://ccb.jhu.edu/software/tophat/ igenomes.shtml. GSEA Pre-ranked 35 was used to perform gene-set enrichment analysis of the described gene signatures on a pre-ranked gene list, setting 1,000 gene-set permutations. GSEA Pre-ranked calculates an enrichment score for each gene set using the Kolmogorov-Smirnov test. The nominal P value estimates the statistical significance of the enrichment score for a single gene set and it was corrected for gene-set size and multiple hypothesis testing. For GSEA analysis, non-expressed genes were removed from the ranking.
ELISA. Total IgG 1 serum titres after 10 d of SRBC immunization were measured by ELISA using mouse IgG1 ELISA kit (Abcam, catalogue no. ab133045) and following the manufacturer's instructions. High-affinity and total NP-specific antibodies were measured by ELISA using 10 mg ml −1 of NP(2.5)-BSA or NP(25)-BSA as the coating reagent, respectively. Serum was assayed in threefold dilutions starting at 1/100. NP-specific IgG1 was detected using goat anti-mouse IgG1 Fcspecific antibody conjugated to horseradish peroxidase (Jackson Immunoresearch, catalogue no. 115-035-071) and developed with tetramethylbenzidine (Sigma, T4319). The optical density OD 450 was measured using a Synergy4 microplate reader (Izasa Scientific). Titres were calculated by logarithmic interpolation of the dilutions with readings immediately above and immediately below an OD 450 of 0.2 (for example, if OD 450 readings at dilution 2 (1/900) = 0.3 and at dilution 3 (1/2,700) = 0.1, then titre = dilution = 2.5 = 1/1,558).
Histological and histochemical analysis of mouse tissues. Tissue samples were fixed in 10% neutral buffered formalin (4% formaldehyde in solution), paraffin embedded and cut at 3 μm, mounted in superfrost plus slides and dried overnight. For different staining methods, slides were deparaffinized in xylene and rehydrated through a series of graded concentrations of ethanol in water. Consecutive sections were stained with haematoxylin and eosin (H&E), and several immunohistochemistry reactions were performed in an automated immunostaining platform (Ventana Discovery XT). Antigen retrieval was first performed with the appropriate pH buffer, (CC1m, Ventana, Roche) and endogenous peroxidase was blocked (peroxide hydrogen at 3%). Then, slides were incubated with the appropriate primary antibody as detailed: rabbit monoclonal anti-PD1 (D7D5W, 1/50, Cell Signaling Technology, catalogue no. 84651), mouse monoclonal anti-Bcl6 (191E/A8; 1/30; CNIO Monoclonal Antibodies Core Unit. catalogue no. AM(191E/A8)) and rabbit polyclonal anti-Cleaved Caspase 3 (1/300, Cell Signaling Technology, catalogue no. 9661). After the primary antibody, slides were incubated with the visualization systems (Omni Map anti-Rabbit, Ventana, Roche) conjugated with horseradish peroxidase. Immunohistochemical reaction was developed using 3,30-diaminobenzidine tetrahydrochloride (DAB) (Chromo Map DAB, Ventana, Roche; DAB Dako) and nuclei were counterstained with Carazzi's haematoxylin. Finally, the slides were dehydrated, cleared and mounted with a permanent mounting medium for microscopic evaluation. Positive control sections known to be primary antibody positive were included for each staining run. For PD1 quantification, whole slides were acquired with a slide scanner (AxioScan Z1, Zeiss). After selection of regions of interest (lymph nodes and spleen), areas for quantification were selected and exported as subsets of images in tiff format. All images were then checked, and those with staining or cutting artefacts were eliminated. Different images from different slides were chosen for quantification programme training (AxioVision v.4.6 software package, Zeiss) and an appropriate script for each antibody was created. For PD1 quantification, positivity was evaluated in one phase (phase 1, positive cells) and compared with total tissue area (phase 2, total cells). After training and script optimization, the quantification programme was run and results exported as Excel files with scoring data for each tiff file. Data obtained were then compiled and appropriately assessed.
Histology and immunohistochemistry FL patient samples. Written consent was obtained for collection and use of patient specimens for research purposes with ethical approval granted by the Health Research Authority: London City and East Research Ethics Committee (REC Ref: 10/H0704/65 and 06/Q0605/69). Immunohistochemistry (IHC) staining was performed in an automated system following the manufacturer's instructions (Leica Bond-Max, Epitope Retrieval Solution 2 AR9640 for 20 min and Bond Polymer Refine Detection DS9800; Leica Microsystems). The primary antibody was a mouse monoclonal anti-PD1, clone NAT105C/E3 lot number 0208, provided by G. Roncador (Monoclonal Antibodies Core Unit, CNIO). Incubation time of the primary antibody was 15 min. The tissue microarray had three punches per biopsy that were distributed discontinuously. The resulting cores had a diameter of 1-1.5 mm. The PD1 analysis was set up as in refs. 72, 73 and was done as follows. First, observation was made using a brightfield Olympus BX63 microscope (Olympus). Then, the slide was scanned at ×400 magnification using a digital pathology system (Hamamatsu NanoZoomer C9600) and visualized with NDP.view2 software (Hamamatsu Photonics). PD1 was quantified on the basis of the expression within the follicles, except when the follicular lymphoma had a completely diffuse pattern. PD1 was measured as 0 (<1%), +1 (1-5%), +2 (5-20%) and +3 (>20%). The analysis of the cores was made without previous knowledge of the mutational status of RRAGC. The value of each core was recorded and the average of the three cores was calculated. Occasional broken cores, with insufficient tissue or inadequate immunohistochemical staining, were excluded from the analysis. Comparisons were made by non-parametric Mann-Whitney U-test, one-tailed and with a priori significance level of 0.05 (www.socscistatistics.com).
Quantification, statistical analysis and reproducibility. The values of n, total number of animals per group, as well as the definition of centre, dispersion and precision measures are reported in each figure and figure legend. Unless otherwise stated, two-sided Student's t-test or chi-squared tests were performed as depicted in the figures. Survival in mouse experiments was represented with Kaplan-Meier curves, and significance was estimated with the log-rank test. Analyses were carried out using Prism software (GraphPad). Further information on statistical parameters, software, study design and reagents used can be found in the Reporting Summary. Fig. 1a were performed four times independently for RagC S74C/+ mice and three times independently for RagC T89N Supplementary Fig. 1g was performed once for each genotype. The experiment in Supplementary Fig. 1h was performed once. The experiment in Fig. 2a ,c-e,g-j was performed once. The experiment in Supplementary Fig. 2a was performed two times independently for each genotype. The experiment in Supplementary  Fig. 2b ,f,g,j,i,l was performed once. The experiment in Supplementary Fig. 2k Supplementary Fig. 3b were performed twice in each genotype showing similar results.
Reproducibility. The experiments in
The experiment in Supplementary Fig. 3c was performed twice showing similar results. The experiments in Supplementary Fig. 3d were performed three times showing similar results. The experiments in Fig. 4b-d and Supplementary  Fig. 4a -c were performed once. The experiments in Fig. 4f ,g,j were performed two times independently showing similar results. The experiments in Fig. 4h and Supplementary Fig. 4h ,i were performed three times independently showing similar results. The experiments in Fig. 4l,m and Supplementary Fig. 4d were performed two times independently for RagC S74C/+ mice and once for RagC T89N/+ mice showing similar results. The experiment in Supplementary Fig. 4f was performed once. The experiments in Supplementary Fig. 4j were performed two times independently for each genotype showing similar results. The experiments in Fig. 5a and Supplementary Fig. 5a -c were each performed once. The experiments in Fig. 5b and Supplementary Fig. 5e were performed five times independently in RagC S74C/+ mice and two times independently in RagC T89N/+ mice showing similar results. The experiments in Fig. 5d were performed three times independently for each genotype showing similar results. The experiments in Fig. 5e-g were performed once. The results obtained in Fig. 5h were validated on a different cohort of FL patients ( Supplementary Fig. 5k ). The experiments in Supplementary Fig. 5d were performed four times independently in RagC S74C/+ mice and five times independently in RagC T89N/+ mice showing similar results. The experiments in Supplementary Fig.  5f ,g,j were performed two times independently showing similar results.
Reporting Summary. Further information on research design is available in the Nature Research Reporting Summary linked to this article.
Data availability
Sequence data that support the findings of this study have been deposited in GEO, with the accession codes GSE125393 and GSE125394. The data that support the findings of this study are available from the corresponding author upon request. The data that support the plots within this paper and other findings of this study are available from the corresponding author upon reasonable request.
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